Last reviewed · How we verify
NCT05729880
Can Ultrasound be Used as a Measure of Muscle Quality? A Validation Study Comparing Ultrasound With MRI and MRS in Older and Younger Persons.
trial testing MRI, MRS in Muscle Atrophy in 30 participants. Completed in 1 April 2023.
16 November 2022
Quick facts
| Lead sponsor | University of Exeter |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 10 June 2022 |
| Primary completion | 16 November 2022 |
| Estimated completion | 1 April 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- MRI, MRS
- Ultrasound
Conditions studied
- Muscle Atrophy — all drugs for Muscle Atrophy →
Sponsor
University of Exeter
Who can join
18 and older, any sex, with Muscle Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to see if ultrasound can be used as a reliable and valid method to measure fatty infiltration, muscle thickness and muscle architecture to provide a quick, cheap and mobile alternative measure of muscle quality to MRI. The MRS and MRI images will be used to validate the ultrasound images.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ultrasound predicts skeletal muscle fat infiltration in healthy middle-aged and young adults: Validation against MRI.
Holsgrove-West RK, Słowiński PM, Svensen E, Koscien C, et al · · 2026 · cited 1× · PMID 41778905 · DOI 10.1113/ep092865
Verify or expand the search:
- PubMed search for NCT05729880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Muscle Atrophy
Currently open trials in the same condition.
- NCT06631053 — FIT Exercise in 30d of ULLS-induced Muscle Disuse · NA · recruiting
- NCT06253104 — Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure · recruiting
- NCT06238609 — Neuromodulation for Prevention of Intensive Care Unit Acquired Weakness and Post Intensive Care Syndrome · NA · active not recruiting
- NCT05919940 — Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) · NA · recruiting
- NCT05627440 — A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure · NA · recruiting
Other University of Exeter trials
Trials by the same sponsor.
- NCT07457437 — Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment · NA · recruiting
- NCT06478121 — Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE) · recruiting
- NCT06965699 — The Effect of a Plant-based, Protein-dense Sauce on Essential Amino Acid Concentrations and Gut Fullness in Older Adults · NA · recruiting
- NCT06846294 — Obesity Prevention in Children and Young People Treated for Acute Lymphoblastic Leukaemia with ALLTogether · NA · not yet recruiting
- NCT06852547 — The Effect of Ingesting a Novel Algae Protein Source on Rested and Exercised Muscle Protein Synthesis Rates in Older Adu · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05729880 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Exeter
- Last refreshed: 9 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05729880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing